Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a
monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to …

Since its introduction, the use of cetuximab in the treatment of head and neck squamous cell
carcinoma (HNSCC) has experienced an evolution. Currently, cetuximab associated with …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

Background Cetuximab, a monoclonal blocking antibody against the epidermal growth
factor receptor EGFR, has been approved for the treatment of squamous cell carcinomas of …

e18061 Background: Cetuximab, a monoclonal antibody against EGFR, is the only
approved targeted therapy for head and neck squamous cell carcinoma (HNSCC), with a …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

BACKGROUND: Cetuximab is an epidermal growth factor receptor (EGFR)-blocking
antibody that has been approved for the treatment of patients with head and neck squamous …

Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and
neck squamous cell carcinoma (HNSCC) but benefits a minority. An established tumor …

Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …

Cetuximab (Erbitux®) is a human-mouse chimeric monoclonal antibody, which competitively
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …